Targeted drug combo for advanced prostate cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer that no longer responds to standard hormone therapy and has spread to other parts of your body.
- Your tumor must have a specific protein called HER2 (detected by a lab test on a biopsy sample).
- You are able to walk and take care of yourself (day-to-day activities aren't severely limited).
- You have good kidney, liver, and blood cell counts based on blood tests done before the trial.
- You haven't had certain previous treatments like PSMA-targeted therapy or strong chemotherapy in the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for men with advanced prostate cancer that has spread to the bones and stopped responding to standard hormone therapy or chemotherapy. The treatment combines an experimental drug (LC-K76) with a type of immunotherapy (anti-PD-1) that helps your immune system fight cancer.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests a new drug called Disitamab Vedotin for men with advanced prostate cancer that is no longer responding to hormone therapy. The drug targets a protein called HER2 on cancer cells to try to shrink or slow the cancer.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.